HER2-low-expressing Gastric Cancer
1 clinical trials · Condition
◉ Watch HER2-low-expressing Gastric Cancer
| Record | Firm | Date |
|---|---|---|
| Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer (NCT06078982) | Shanghai East Hospital | 2023-06-06 |
Track HER2-low-expressing Gastric Cancer automatically
Every clearance here is in the API, with alerts when new ones post.